 |
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2010, vol. 16, book 3
Subject Collection: Medicine
Page: 74 - 77
DOI: 10.5272/jimab.1632010_74
Online date: March 18, 2011
J of IMAB 2010; 16(3):74-77
CAPECITABINE AND IRINOTECAN AS FIRST- LINE CHEMOTHERAPY FOR PATIENTS WITH METASTATIC COLORECTAL CANCER
Deyan Davidov,
Department of Chemotherapy, Oncological Center, Medical University, Pleven, Bulgaria
ABSTRACT:
Objectives: Capecitabine is an oral fluoropyrimidine carbamate that is at least as effective than Fluorouracil / Leucovorin as first- line treatment for patients with metastatic colorectal cancer /CRC/. The topoisomerase I inhibitor Irinotecan has shown consistent efficacy in chemotherapy- naive patients. The aim of this study was to determine the efficacy and tolerability of Capecitabine in combination with Irinotecan /XELIRI/ as first- line therapy in patients with advanced CRC. Methods: In the period 2007- 2009 twenty-one consecutive patients with metastatic CRC entered the study. The treatment schedule consists of Capecitabine 1250 mg/m2 p.o. twice daily for 14 days with a 7- day rest period and intravenous Irinotecan 180mg/m2 day 1 with repetition of courses every 21 days. Results: Overall response rate was 33,3%. Median time to progression and overall survival was 7,6 months and 15,6 months, respectively. The most common grade 3- 4 adverse events were diarrhea and neutropenia. There were no treatment- related deaths. Conclusion: These results indicate that XELIRI is a potentially feasible and clinically active regimen in patients with advanced CRC.
Key words: Metastatic colorectal cancer, Capecitabine, Irinotecan, First- line chemotherapy, Survival.
Page: 74-77; FULL TEXT PDF (120 KB) Abstract & References
Please include this information when citing this paper: DOI: 10.5272/jimab.1632010_74